As of January 2026, the leading pharmaceutical R&D project was Retatrutide by Eli Lily with a net present value of about 29 billion U.S. dollars. Amycretin from Novo Nordisk followed as the second leading project with a net present value of approximately 21 billion U.S. dollars.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Evaluate. (January 7, 2026). Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 14, 2026, from /statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate. "Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars)." Chart. January 7, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 14, 2026. /statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate. (2026). Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 14, 2026. /statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate. "Leading Pharmaceutical R&d Projects Based on Net Present Value (Npv) as of January 2026 (in Billion U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 7 Jan 2026, /statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate, Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/973453/most-valuable-randd-projects-by-npv/ (last visited July 14, 2026)
Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars) [Graph], Evaluate, January 7, 2026. [Online]. Available: /statistics/973453/most-valuable-randd-projects-by-npv/
